Track ProMIS Neurosciences Inc. Common Shares — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

ProMIS Neurosciences Inc. Common Shares PMN · Stock Open ProMIS Neurosciences Inc. Common Shares in new tab

3.29 USD
EPS
-11.65
P/B
0.63
ROE
-172.30
Beta
-0.21
Target Price
41.96 USD
Loading chart...
Key Metrics
Earnings dateMarch 24, 2027
EPS-11.65
Book Value5.51
Price to Book0.63
% Insiders12.294%
Estimates
Forward P/E-0.75
Forward EPS-4.60
Target Mean Price41.96

DCF valuation

Model fair value for ProMIS Neurosciences Inc. Common Shares (PMN)
Result
Sign in to run the valuation for PMN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
6 analysts · consensus Strong buy · mean target 41.96 USD (low 14.70, high 98.01) · as of 12 Nov 2026
Low 14.70
Mean 41.96
High 98.01
Price 3.29
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

ProMIS Neurosciences Inc. Common Shares Logo ProMIS Neurosciences Inc. Common Shares Analysis (PMN)

Canada Health Care Official Website Stock

Is ProMIS Neurosciences Inc. Common Shares a good investment? ProMIS Neurosciences Inc. Common Shares (PMN) is currently trading at 3.29 USD. Market analysts have a consensus price target of 41.96 USD. This suggests a potential upside from current levels.

Earnings Schedule: ProMIS Neurosciences Inc. Common Shares is expected to release its next earnings report on March 24, 2027. The market consensus estimate for Forward EPS is -4.60.

Investor FAQ

Does ProMIS Neurosciences Inc. Common Shares pay a dividend?

No, it does not currently pay a dividend.

What asset class is ProMIS Neurosciences Inc. Common Shares?

ProMIS Neurosciences Inc. Common Shares is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 24, 2027. The company currently has a trailing EPS of -11.65.

Company Profile

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.

Exchange Ticker
FRA (Germany) 23J.F
NMS (United States) PMN
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
June 28, 2022 1:60
Nov. 28, 2025 1:25
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion